Literature DB >> 29410932

A Developmental History of the Positive and Negative Syndrome Scale (PANSS).

Stacy Liechti1,2,3,4, Gianna Capodilupo1,2,3,4, Douglas J Opler1,2,3,4, Mark Opler1,2,3,4, Lawrence H Yang1,2,3,4.   

Abstract

Psychometric instruments are products of their time-Their designs and initial purposes are influenced and shaped by the contemporary treatment regimens, context, and cultural and conceptual biases of their developers. In this review article, the authors explore the history of the most influential schizophrenia research tools that have been created over the past several decades. The authors describe the scientific concepts, cultural influences, and challenges of past and present researchers as they strive to develop better assessment tools for schizophrenia. Starting with Moore's Scheme for the Quantitative Measurement of Abnormal Emotional Condition, developed in the early 1900s, and concluding with Kay, Fiszbein, and Opler's Positive and Negative Syndrome Scale, developed in the 80s, the authors describe several scales and illustrate how each scale led to and influenced the development of a later scale. The authors hope that a better understanding of schizophrenia assessment tool evolution and limitations will assist in the development of new instruments that better address the global needs for the evaluation, research, and treatment of psychosis.

Entities:  

Keywords:  Brief Psychiatric Rating Scale (BPRS); Inpatient Multidimensional Psychiatric Scale (IMPS); Multidimensional Scale for Rating Psychiatric Patients (MSRPP); Positive and Negative Syndrome Scale (PANSS); psychometrics; psychosis; symptoms

Year:  2017        PMID: 29410932      PMCID: PMC5788246     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN: 2158-8333


  18 in total

Review 1.  Whose evidence? Lessons from the philosophy of science and the epistemology of medicine.

Authors:  E Harari
Journal:  Aust N Z J Psychiatry       Date:  2001-12       Impact factor: 5.744

2.  Drug-action profiles based on an abbreviated psychiatric rating scale.

Authors:  D R GORHAM; J E OVERALL
Journal:  J Nerv Ment Dis       Date:  1960-12       Impact factor: 2.254

3.  Factors descriptive of chronic schizophrenics selected for the operation of prefrontal lobotomy.

Authors:  M LORR; R L JENKINS; J Q HOLSOPPLE
Journal:  J Consult Psychol       Date:  1954-08

4.  Rating scales and check lists for the evaluation of psychopathology.

Authors:  M LORR
Journal:  Psychol Bull       Date:  1954-03       Impact factor: 17.737

5.  A factor-analytic study of schizophrenic symptoms.

Authors:  W H GUERTIN
Journal:  J Consult Psychol       Date:  1952-08

6.  The generality of psychiatric syndromes.

Authors:  J R WITTENBORN; J D HOLZBERG
Journal:  J Consult Psychol       Date:  1951-10

7.  Can categorical and dimensional views of psychiatric illness be distinguished?

Authors:  D A Grayson
Journal:  Br J Psychiatry       Date:  1987-09       Impact factor: 9.319

8.  Differential effects of amphetamine and neuroleptics on negative vs. positive symptoms in schizophrenia.

Authors:  B Angrist; J Rotrosen; S Gershon
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

Review 9.  Molecular pathology of schizophrenia: more than one disease process?

Authors:  T J Crow
Journal:  Br Med J       Date:  1980-01-12

10.  Positive and negative schizophrenic symptoms and the role of dopamine.

Authors:  T J Crow
Journal:  Br J Psychiatry       Date:  1980-10       Impact factor: 9.319

View more
  2 in total

1.  Scalability of the Positive and Negative Syndrome Scale in first-episode schizophrenia assessed by Rasch models.

Authors:  Lone Baandrup; Peter Allerup; Mette Ø Nielsen; Signe W Düring; Kirsten B Bojesen; Stefan Leucht; Silvana Galderisi; Armida Mucci; Paola Bucci; Celso Arango; Covadonga M Díaz-Caneja; Paola Dazzan; Philip McGuire; Arsime Demjaha; Bjørn H Ebdrup; Wolfgang W Fleischhacker; René S Kahn; Birte Y Glenthøj
Journal:  Acta Psychiatr Scand       Date:  2022-04-22       Impact factor: 7.734

2.  Clinical validity of the 12-item WHODAS-2.0 in a naturalistic sample of outpatients with psychotic disorders.

Authors:  Christopher Holmberg; Andreas Gremyr; Jarl Torgerson; Kirsten Mehlig
Journal:  BMC Psychiatry       Date:  2021-03-10       Impact factor: 3.630

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.